Professional development Vacancies

Regarding amendments to the package insert (instructions for medical use) of medicinal products containing phenylephrine (ophthalmic formulations)

17.11.2020 Updated 26.11.2020 3223 views

Based on the assessment of periodic safety update reports for medicinal products containing phenylephrine (ophthalmic formulations), the PRAC Committee made the following scientific conclusions.

Given the available data on the pediatric population from the literature and spontaneous reports, the PRAC considers that 10% phenylephrine (ophthalmic formulations) is not recommended for use in children aged 12 to 18 years, and the age specification of the contraindications for use in children should also be further clarified. The PRAC concluded that the instructions for medical use of medicinal products containing 10% phenylephrine (ophthalmic formulations) should be amended accordingly.

An update of the sections “Method of administration and doses” and “Special precautions for use” of the instructions for medical use is required in order to add recommendations for use in children aged 12 to 18 years.

An update of the sections “Method of administration and doses”, “Contraindications” and “Special precautions for use” of the instructions for medical use is required in order to clarify the age specifications of the contraindications for use in children.

The CMDh agrees with the scientific conclusions of the PRAC.

Grounds for amendments

Based on the scientific conclusions regarding medicinal products containing phenylephrine (ophthalmic formulations), the CMDh is of the opinion that the benefit/risk balance of these medicinal products remains unchanged, taking into account the proposed changes to the instructions.

The following changes to the instructions for medical use of medicinal products containing phenylephrine (ophthalmic formulations) are recommended (new text underlined).

  • into the "Dosage and Administration" section:

Pediatric population

<product name> is contraindicated in children under 12 years of age (see the “Contraindications” section). There are no data on use in children aged 12 to 18 years. < product name> is not recommended for these patients;

  • to the “Contraindications” section:

Children under 12 years of age (see the “Special precautions for use” section);

  • into the “Special warnings and precautions for use” section

Pediatric population

Use in children under 12 years of age is contraindicated because serious systemic adverse reactions have been reported with the use of medicinal products containing phenylephrine (ophthalmic formulations).

Use in children aged 12 to 18 years is not recommended because there is insufficient clinical experience.

Linkhttps://www.ema.europa.eu/en/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments/00010402/202001_en.pdf

Перелік лікарських засобів, що містять phenylephrine (ophthalmic formulations) 10% і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 05.11.2020)